Mindpeak AI Featured in first-of-its Kind Study on Neuroendocrine Neoplasms

Ki-67 + SSRT2A NEN Pilot Study featuring Mindpeak GmbH
We’re excited to share that our AI-powered pathology algorithms were an integral part in a pioneering study on AI-assisted SSRT2A and Ki-67 readout in neuroendocrine neoplasms (NEN). T
he work was recently presented at the 22nd ENETS Conference in Krakow, Poland by PD Dr. med. Daniel Kaemmerer.
The study demonstrated that Mindpeak’s AI delivers clinical-grade performance for IHC scoring in NEN:
✅ 92% agreement with manual evaluation for SSTR2A (pos. vs. neg.)
✅ High interobserver reliability for Ki-67 (Krippendorff's α = 0.83)
✅ System usability score (SUS) of 75 (Grade B)
This proof-of-concept marks another step forward on our mission to bring AI-assisted diagnostics into broad routine pathology, supporting pathologists for more efficient, accurate and reproducible diagnoses.
“AI is not replacing pathologists—it’s empowering them!” summarizes Dr. Kämmerer.
"This study confirmed that AI-powered digital pathology is no longer a vision for the future—it’s a reality today. With high accuracy and usability, Mindpeak’s AI software can support pathologists in making faster, more reliable diagnoses."
A huge thank you to PD Dr. med. Daniel Kaemmerer and the research team for pioneering AI use in neuroendocrine neoplasms.
You may also be interested in
Find out more about our AI-based diagnostics
